http://www.pharmaasia.comPharmaAsia - Clinical Trialsen-USCopyright 2012 Ten Alps Communications Asia. All rights reserved.Thu, 9 Feb 2012 19:19:08 +0800http://www.pharmaasia.com/article/life-technologies-appoints-president-of-medical-sciences/9325Life Technologies announced that Ronnie Andrews, former CEO of Clarient and Segment Leader, GE Molecular Diagnostics, has joined the company as president, medical sciences.http://www.pharmaasia.com/article/life-technologies-appoints-president-of-medical-sciences/9325Fri, 10 Feb 2012 00:00:00 +0800http://www.pharmaasia.com/article/research-based-pharmaceutical-industry-pledges-14-billion-treatments-to-help-end-nine-neglected-tropical-diseases/9324The research-based pharmaceutical industry announced donations of 14 billion treatments this decade to support the elimination or control of nine key neglected tropical diseases (NTDs). Averaging 1.4 billion treatments annually, the donations build upon companies’ existing medicines donation programs which already reach millions of people around the world.http://www.pharmaasia.com/article/research-based-pharmaceutical-industry-pledges-14-billion-treatments-to-help-end-nine-neglected-tropical-diseases/9324Thu, 9 Feb 2012 00:00:00 +0800http://www.pharmaasia.com/article/agilent-technologies-s-thought-leader-award-supports-chris-evelo-s-work-at-maastricht-university/9321Agilent Technologies the Agilent Technologies Foundation announced that Dr Chris Evelo and the department of bioinformatics at Maastricht University are the recipients of an Agilent Thought Leader Award supporting development of software to integrate different types of biological data. The goal of this award is to help accelerate breakthroughs in disease research by facilitating integrative systems biology approaches.http://www.pharmaasia.com/article/agilent-technologies-s-thought-leader-award-supports-chris-evelo-s-work-at-maastricht-university/9321Mon, 6 Feb 2012 00:00:00 +0800http://www.pharmaasia.com/article/phase-iii-studies-with-vegf-trap-eye-in-wet-age-related-macular-degeneration-show-sustained-improvement-in-visual-acuity/9306Bayer HealthCare and Regeneron Pharmaceuticals announced that in an integrated analysis of two parallel Phase III studies (VIEW 1 and VIEW 2) in patients with the neovascular form of age-related macular degeneration (wet AMD), patients treated with VEGF Trap-Eye showed a sustained improvement in visual acuity at 96 weeks versus baseline.http://www.pharmaasia.com/article/phase-iii-studies-with-vegf-trap-eye-in-wet-age-related-macular-degeneration-show-sustained-improvement-in-visual-acuity/9306Wed, 25 Jan 2012 00:00:00 +0800http://www.pharmaasia.com/article/molecular-profiles-invests-in-new-facility-to-increase-manufacturing-capabilities-for-clinical-trials/9304Molecular Profiles, a leading specialist contract research and manufacturing organization, announces the commencement of construction of a new manufacturing facility. This £9 million investment will allow Molecular Profiles to expand its current manufacturing capabilities while strengthening its existing expertise in the drug development field.http://www.pharmaasia.com/article/molecular-profiles-invests-in-new-facility-to-increase-manufacturing-capabilities-for-clinical-trials/9304Thu, 19 Jan 2012 00:00:00 +0800http://www.pharmaasia.com/article/icon-wins-award-at-the-annual-scrip-awards/9303ICON has won the Clinical Research Team of the Year award at the annual 2011 Scrip Awards.http://www.pharmaasia.com/article/icon-wins-award-at-the-annual-scrip-awards/9303Wed, 18 Jan 2012 00:00:00 +0800http://www.pharmaasia.com/article/pbl-interferonsource-collaborates-with-avanza/9300PBL InterferonSource (PBL) and AVANZA Laboratories announced collaboration between their two organizations that will focus on enhancing their ability to service the biopharmaceutical industry.http://www.pharmaasia.com/article/pbl-interferonsource-collaborates-with-avanza/9300Fri, 13 Jan 2012 00:00:00 +0800http://www.pharmaasia.com/article/icon-acquires-beijingwits-medical-consulting/9299ICON has agreed, subject to closing conditions, to acquire BeijingWits Medical Consulting, a leading CRO in China. The transaction is expected to close in the first quarter of 2012.http://www.pharmaasia.com/article/icon-acquires-beijingwits-medical-consulting/9299Wed, 11 Jan 2012 00:00:00 +0800http://www.pharmaasia.com/article/us-government-hiv-aids-clinical-trial-sites-to-accelerate-completion-of-phase-iii-tb-drug-trial/9296The TB Alliance announces the launch of a collaboration with the National Institute of Allergy and Infectious Diseases’ (NIAID) AIDS Clinical Trial Group (ACTG) to conduct and help complete a Phase III clinical trial testing potentially faster-acting tuberculosis (TB) treatments.http://www.pharmaasia.com/article/us-government-hiv-aids-clinical-trial-sites-to-accelerate-completion-of-phase-iii-tb-drug-trial/9296Mon, 9 Jan 2012 00:00:00 +0800http://www.pharmaasia.com/article/viromed-receives-approval-for-phase-ii-trial-in-the-us-for-diabetic-peripheral-neuropathy/9293ViroMed announced that VM202-DPN, the company's proprietary DNA medicine for treatment of diabetic peripheral neuropathy, has received approval from the US FDA for a Phase II clinical trial.http://www.pharmaasia.com/article/viromed-receives-approval-for-phase-ii-trial-in-the-us-for-diabetic-peripheral-neuropathy/9293Wed, 4 Jan 2012 00:00:00 +0800